Available Until 12/13/2022

Clinical Sessions for Recertification: Oncology (Cert # L219365)

ACPE Numbers: Various – see listing below
Pre-Sale Date: N/A
Content Release Date: 12/15/2021
Expiration Date: 12/13/2022
Activity Type: Application-based
CE Credits: 4.0 (BPS and ACPE) contact hours
Activity Fee: $150 (ASHP member); $250 (non-member)

Activity Overview

The Clinical Sessions Package is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). Using a case-based approach, the activities provide high-level, interactive discussions on contemporary and emerging issues in oncology. 

The Oncology Clinical Sessions Recertification Package consists of 2 activities (see table below) and provides up to 4.0 contact hours of continuing pharmacy education and/or recertification credit.   

These activities are part of the ASHP and ACCP professional development program for BCOP recertification approved by the BPS.

The American Society of Health-System Pharmacists and the American College of Clinical Pharmacy are accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

These recertification activities are intended for board certified pharmacists seeking to update their knowledge and skills in:

  • Multiple Myeloma
  • Cancer-Associated Thrombosis

Board certified pharmacists are eligible to receive up to 4.0 contact hours of recertification credit for completing this package. To earn recertification credit, learners must review the activity content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment. 

Recertification credit is earned in the calendar year in which you pass the recertification assessment.

Learning Activity

ACPE Number

Contact Hours (ACPE & BPS)


Recertification Assessment

Updates on Immunotherapy and Best Pharmacy Practice for Multiple Myeloma

0217-9999-21-157-H01-P 2.00 BCOP


Beyond the CLOT: Panel Discussion about Updates in Cancer-Associated Thrombosis





Updates on Immunotherapy and Best Pharmacy Practice for Multiple Myeloma
ACPE Number: 0217-9999-21-157-H01-P

At the conclusion of this application-based educational activity, participants should be able to do the following:

  • Identify the role of and management strategies for novel antibody-based immunotherapy in multiple myeloma treatment approaches.
  • Describe the use of CAR T-cell and bispecific T-cell engager therapies targeting B-cell maturation antigen (BCMA) and in combination with other agents in multiple myeloma.
  • Interpret barriers to care with novel immunotherapeutics in multiple myeloma treatment.
  • Identify strategies for overcoming barriers to optimize access to novel agents and improve the patient experience.
  • Apply best pharmacy practice considerations to the current and evolving myeloma treatment landscape. 

Beyond the CLOT: Panel Discussion about Updates in Cancer-Associated Thrombosis
ACPE Number: 0217-9999-21-156-H01-P

At the conclusion of this application-based educational activity, participants should be able to do the following:

  • Evaluate the literature surrounding updates in the prevention of venous thromboembolism in cancer patients in an ambulatory and inpatient setting.
  • Interpret the evidence surrounding updates in the treatment of venous thromboembolism in cancer patients.
  • Recommend therapeutic options for both prevention and treatment of venous thromboembolism in cancer patients. 

Faculty bios

Justin Arnall, Pharm.D., BCOP
Clinical Coordinator, Bleeding Disorders & Hematology
Specialty Pharmacy Service/ Atrium HealthCharlotte, North Carolina 

John Bossaer, Pharm.D., BCPS, BCOP
East Tennessee St. University
Bill Gatton College of Pharmacy
Johnson City, Tennessee 

Courtney C. Cavalieri, Pharm.D., BCOP*
Clinical Oncology Pharmacist
Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah 

Elizabeth Dow-Hillgartner, Pharm.D., BCOP, BCPS
Clinical Pharmacist, Hematology/Oncology
UW Health
Madison, Wisconsin 

Karen M. Fancher, Pharm.D., BCOP*
Associate Professor of Pharmacy Practice/ Clinical Pharmacy Specialist - Oncology
Duquesne University School of Pharmacy/UPMC Passavant Hospital
Pittsburgh, Pennsylvania 

Mitchell E. Hughes, Pharm.D., BCPS, BCOP
Clinical Pharmacy Specialist, Hematology/Oncology/Cellular Therapy, Lymphoma Program and Lymphoma Translational Research
Perelman Center for Advanced Medicine
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania

Lisa Lohr, Pharm.D., BCOP, BCPS
Masonic Cancer Clinic
M Health/Fairview
Minneapolis, Minnesota 

Donald C. Moore, Pharm.D., BCPS, BCOP, DPLA
Pharmacist Clinical Coordinator – Hematology/Oncology
Levine Cancer Institute, Atrium Health
Concord, North Carolina

Danielle Roman, Pharm.D., BCOP*
Manager, Oncology Clinical Pharmacy Services
Allegheny Health Network
Pittsburgh, Pennsylvania 

Christine M. Walko, Pharm.D., BCOP, FCCP*
Associate Member and Personalized Medicine Specialist
DeBartolo Family Personalized Medicine Institute
H. Lee Moffitt Cancer Center
Associate Professor, Department of Oncologic Sciences
USF Morsani College of Medicine
Tampa, Florida 

*Content Matter Experts

Donald Moore, Pharm.D., BCPS, BCOP, DPLA
Kelly K. Nystrom, Pharm.D., BCOP
Amanda N. Seddon, Pharm.D., BCPS, BCOP

Hannah Alley, Pharm.D., BCOP
Marina Barsoum, Pharm.D., BCOP
Jon  Crowley, Pharm.D., BCOP
Colleen Herman, Pharm.D., BCOP
Tarah Hibbs, Pharm.D., BCOP
Hailey Hill, Pharm.D., BCOP
Brooke Hueftle, Pharm.D., BCOP
Jeremiah Jessee, Pharm.D., BCOP
Leonette Kemp, Pharm.D., BCOP
Matthew Lariviere, Pharm.D., BCOP
Weiyi (Andrew) Li, Pharm.D., BCOP
Beth Loomis, Pharm.D., BCOP
Jessica McElwee, Pharm.D., BCOP
Sweta Patel, Pharm.D., BCOP
Alexandra Payne, Pharm.D., BCOP
Cassandra Perkey, Pharm.D., BCOP
Connor Roth, Pharm.D., BCOP
Michelle Schroeder, Pharm.D., BCOP
Natalie Schulze, Pharm.D., BCOP
Bethany Sibbitt, Pharm.D., BCOP
Gregory Sneed, Pharm.D., BCOP
Anna Suwala, Pharm.D, BCOP
Adrian Tsui, Pharm.D., BCOP
Malgorzata Tyszka, B.Sc.Pharm, BCOP
Justin Woods, Pharm.D., BCPS, BCOP
Carolnn Yong, Pharm.D., BCPS, BCOP

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Standards for Commercial Support, ASHP requires that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual of his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring the in the last 12 months with a commercial interest whose products or series may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content. 

All faculty and planners for ACCP and ASHP education activities are qualified and selected by ACCP and ASHP required to disclose any relevant financial relationships with commercial interests. ACCP and ASHP identifies and resolves conflicts of interest prior to an individual’s participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.

  • Justin Arnall is a speaker on the Novo Nordisk (bleeding disorders) speakers’ bureau.
  • Donald C. Moore reports advisory board participation and consulting fees from Oncopeptides.
  • Mitchell E. Hughes reports the following disclosures: AcertaPharma and HOPA (Research Funding), AstraZeneca (Advisory Board), Genzyme (Advisory Board), Janssen (Advisory Board), AbbVie (Advisory Board), Karyopharm(Advisory Board)

All other planners, presenters, reviewers, ACCP and ASHP staff and others with an opportunity to control content report no financial relationships relevant to this activity.

Activities which can be completed in any order. Each activity consists of audio, video, and/or PDFs and evaluations.  Learners must review all content and complete the evaluations to receive continuing pharmacy education credit for each activity. 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

These activities were developed by ASHP and ACCP.